Changing antiretroviral therapy in the setting of virologic relapse: Review of the current literature

被引：11

作者：

Anderson A.M.L. ^{[1
]}

Bartlett J.A. ^{[1
]}

机构：

[1] Box 3824, Duke University Medical Center, Durham

来源：

Current HIV/AIDS Reports | 2006年 / 3卷 / 2期

关键词：

Atazanavir; Acquir Immune; Adefovir Dipivoxil; Virologic Suppression; Multicenter AIDS Cohort Study;

D O I：

10.1007/s11904-006-0022-1

中图分类号：

学科分类号：

摘要：

Virologic relapse after initial virologic suppression remains a concern for patients on antiretroviral therapy (ART). Multiple factors may contribute to virologic relapse, including suboptimal adherence, resistance, and pharmacokinetic issues. The major guidelines for HIV care are in agreement that ART regimen change is indicated in relapse because resistance is identified, but the guidelines are not completely clear on the timing of regimen change. When relapse occurs due to resistance, patients may continue with viremia well below their set points, stable or increasing CD4 + counts, and clinical health for several years. However, delaying a switch in the treatment regimen may lead to the accumulation of resistance which compromises future treatment response. In general, a lower switch threshold is recommended for patients during relapse on first or second line regimens. Copyright © 2006 by Current Science Inc.

引用

页码：79 / 85

页数：6

共 49 条

[1]

Detels R., Munoz A., McFarlane G., Et al., Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration, JAMA, 280, pp. 1497-1503, (1998)

[2]

Palella Jr. F.J., Delaney K.M., Moorman A.C., Et al., Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection, N Engl J Med, 338, pp. 853-860, (1998)

[3]

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, (2005)

[4]

Yeni P.G., Hammer S.M., Hirsch M.S., Et al., Treatment for adult HIV infection: 2004 Recommendations of the International AIDS Society-USA Panel, JAMA, 292, pp. 251-265, (2004)

[5]

Chen R.Y., Westfall A.O., Mugavero M.J., Et al., Duration of highly active antiretroviral therapy regimens, Clin Infect Dis, 37, pp. 714-722, (2003)

[6]

D'Arminio M.A., Lepri A.C., Rezza G., Et al., Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients, AIDS, 14, pp. 499-507, (2000)

[7]

Van Roon E.N., Verzijl J.M., Juttmann J.R., Et al., Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants, J Acquir Immune Defic Syndr Hum Retrovirol, 20, pp. 290-294, (1999)

[8]

Anderson J., BHIVA Guidelines for the Treatment of HIV-Infected Adults with Antiretroviral Therapy

[9]

Le Moing V., Chene G., Carried M.P., Et al., Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen, AIDS, 16, pp. 21-29, (2002)

[10]

Mocroft A., Ruiz L., Reiss P., Et al., Virological rebound after suppression on highly active antiretroviral therapy, AIDS, 17, pp. 1741-1751, (2003)

← 1 2 3 4 5 →